Immune-Mediated Inflammatory Diseases, Dyslipidemia, and Cardiovascular Risk: A Complex Interplay

Area of Science:

• Cardiovascular Medicine
• Rheumatology
• Pharmacology

Background:

• Autoimmune inflammatory diseases (e.g., lupus, rheumatoid arthritis, psoriasis) significantly increase cardiovascular disease (CVD) risk.
• These conditions promote a proatherogenic dyslipidemic state, involving dysfunctional high-density lipoproteins (HDL) and oxidized low-density lipoproteins (LDL).
• Lipid profiles are influenced by disease activity and immunosuppressive medications, complicating risk assessment.

Purpose of the Study:

• To critically evaluate the link between immune-mediated inflammatory diseases and dyslipidemia.
• To explore mechanisms of atherogenesis in this context.
• To assess the impact of pharmacotherapies on lipid profiles and CVD risk.

Main Methods:

• Literature review of studies on autoimmune diseases, dyslipidemia, and cardiovascular risk.
• Analysis of mechanisms underlying inflammation-induced lipid alterations.
• Evaluation of the effects of disease-modifying antirheumatic drugs (DMARDs) and lipid-lowering therapies on lipid profiles.

Main Results:

• Autoimmune diseases commonly induce dyslipidemia, characterized by altered HDL and LDL function, contributing to atherosclerosis.
• Disease activity and specific DMARDs variably impact lipid metabolism and cardiovascular risk.
• Lipid-lowering therapies, including statins, are essential for managing residual cardiovascular risk.

Conclusions:

• Dyslipidemia is a key contributor to elevated cardiovascular risk in autoimmune inflammatory diseases.
• Personalized management strategies considering disease specifics and medication effects are necessary.
• Emerging therapies combining anti-inflammatory and lipid-lowering properties hold promise for improved outcomes.